3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma
6
Lymphoma, Mantle-Cell
3
Lymphoma, Follicular
3
Lymphoma, Non-Hodgkin
2
Waldenstrom Macroglobulinemia
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Diffuse Large B-Cell Lymphoma Refractory
1
Burkitt Lymphoma
1
Interventions
loncastuximab tesirine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Diffuse Large B-Cell Lymphoma Refractory
×
loncastuximab tesirine
×
Clear all
NCT03589469
2023-08-29
LOTIS-2
ADC Therapeutics S.A.
Phase 2
Completed
145 enrolled
24 charts
1 FDA